Zhang Xiuying, Sun Haidan, Paul Sanjoy K, Wang Quanhui, Lou Xiaomin, Hou Guixue, Wen Bo, Ji Linong, Liu Siqi
Department of Endocrinology and Metabolism, Peking University People's Hospital, Peking University Diabetes Centre, No. 11, Xi Zhi Men Nan Da Jie, Xicheng District, Beijing, 100044 China.
CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, 100101 China.
Clin Proteomics. 2017 May 17;14:19. doi: 10.1186/s12014-017-9154-0. eCollection 2017.
The Xiaoke Pill containing Chinese herb extracts and Glibenclamide, is used in therapy for type 2 diabetes mellitus (T2DM), and is effective in reducing the risk of hypoglycemia and improving diabetes symptoms compared with Glibenclamide. We describe a quantitative proteomics project to measure the T2DM serum proteome response to the Xiaoke Pill and Glibenclamide.
Based on a recently conducted 48-week clinical trial comparing the safety and efficacy of Glibenclamide (n = 400) and Xiaoke Pill (n = 400), after matching for age, sex, BMI, drug dose and whether hypoglycemia occurred, 32 patients were selected for the serum based proteomic analysis and divided into four groups (with/without hypoglycemia treated with Xiaoke Pill or Glibenclamide, n = 8 for each group). We screened the differential serum proteins related to treatments and the onset of hypoglycemia using the iTRAQ labeling quantitative proteomics technique. Baseline and follow-up samples were used.
The quantitative proteomics experiments demonstrated that 25 and 21 proteins differed upon treatment with the Xiaoke Pill in patients without and with hypoglycemia, respectively, while 24 and 25 proteins differed upon treatment with Glibenclamide in patients without and with hypoglycemia, respectively. The overlap of different proteins between the patients with and without hypoglycemia given the same drug treatment was much greater than between the patients given different drug treatments.
We conclude that the serum proteins response to the two different anti-diabetic drug treatments may serve as a sensitive biomarker for evaluation of the therapeutic effects and continue investigations into the mechanism.
消渴丸含有中药提取物和格列本脲，用于治疗2型糖尿病（T2DM），与格列本脲相比，能有效降低低血糖风险并改善糖尿病症状。我们描述了一个定量蛋白质组学项目，以测量T2DM血清蛋白质组对消渴丸和格列本脲的反应。
基于最近进行的一项为期48周的比较格列本脲（n = 400）和消渴丸（n = 400）安全性和有效性的临床试验，在匹配年龄、性别、BMI、药物剂量以及是否发生低血糖后，选择32例患者进行基于血清的蛋白质组学分析，并分为四组（消渴丸或格列本脲治疗且有/无低血糖，每组n = 8）。我们使用iTRAQ标记定量蛋白质组学技术筛选与治疗和低血糖发作相关的差异血清蛋白。使用基线和随访样本。
定量蛋白质组学实验表明，在无低血糖和有低血糖的患者中，分别有25种和21种蛋白质在接受消渴丸治疗后有所不同，而在无低血糖和有低血糖的患者中，分别有24种和25种蛋白质在接受格列本脲治疗后有所不同。接受相同药物治疗的有低血糖和无低血糖患者之间不同蛋白质的重叠程度远大于接受不同药物治疗的患者之间。
我们得出结论，血清蛋白对两种不同抗糖尿病药物治疗的反应可能作为评估治疗效果的敏感生物标志物，并继续对其机制进行研究。
